Recombinant immunotoxins for cancer therapy

Expert Opinion on Biological Therapy

Volumn 1, Issue 4, 2001, Pages 693-702

  Brinkmann, Ulrich ^a   Keppler Hafkemeyer, Andréa ^b   Hafkemeyer, Peter ^c  

^a Pharmacogenetics Lab   (Germany)

^b Cellgenix GmbH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apoptosis; Diphteria toxin; Haematological malignancy; Pseuaomonasaovmn; Recombinant antibody; Ricin; Solid tumour; Toxin

Indexed keywords

CANCER ANTIBODY; HYBRID PROTEIN; IMMUNOTOXIN; TUMOR ANTIGEN;

ANIMAL; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN ENGINEERING; PROTEIN SECONDARY STRUCTURE; REVIEW;

ANIMAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMAN; IMMUNOTOXINS; NEOPLASMS; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS;

EID: 0035408036     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.4.693     Document Type: Article

References (87)

1. LANDISSH, MURRAY T.BOLDENS, WINGO PA: Cancer statistics, 1998. CA Cancer J. Clin. (1998) 48:6-29.
2. BRINKMANN U, PASTANI: Recombinant Immunotoxins: from basic research to cancer therapy. Methods (1995) 8:143-156.
3. PAI LH, PASTAN I: Immunotoxins and recombinant toxins for cancer treatment. Important. Adv. OncoL (1994):3-19.
4. BRINKMANN U, PASTAN I: Immunotoxins against cancer. Biochim. Biofhys. Aaa. (1994) 27:27-45.
5. KREITMAN RJ, PASTAN I: Immunotoxins for targeted cancer therapy. Adv. DrugDcliv. Rev. (1998) 31:53-88.
6. HAFKEMEYER P, BRINKMANN U, GOTTESMAN MM, PASTAN I: Apoptosis induced by Pseudomonas Exotoxin: a sensitive and rapid marker for gene delivery in vivo. Hum.Gene Ther. (1999) 10:923-934.
7. KEPPLER-HAFKEMEYERA, BRINKMANN U, PASTAN I: Role of caspases in immunotoxin induced apoptosis of cancer cells. Biochemistry (1998) 37:16934-16942.
8. KEPPLER-HAFKEMEYERA, KREITMAN RJ, PASTAN I: Apoptosis induced by Immunotoxins used in the treatment of hématologie malignancies. Int. J. Cancer (2000) 87:86-94.
9. WALDMAN TA: The interleukin-2 receptor. J. BioL Chem. (1991) 266:2681-2684.
10. LORIMERIAJ, WIKSTRAND CJ, BATRA SK, BIGNER DD, PASTAN I: Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumours. Clin. Cancer Res. (1995) 1:859-864.
11. PASTAN I, LOVELACE ET, GALLO M, RUTHERFORD AV, MAGNANIJL, WILLINGHAM MG Characterization of monoclonal antibodies Bl and B3 that react with mucinous adenocarcinomas. Cancer Res. (1991) 51:3781-3787.
12. CHANGK, PASTAN I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancer. Proc. NatL Acad. Sei. USA (1996) 93:136-140.
13. BUCHNERJ, RUDOLPH R: Renaturation, purification and characterisation of recombinant Fab fragments produced in £
14. coli. Biotechnology (1991) 9:157-162.
15. BIRD RE, HARDMAN KD, JACOBSEN JW et al.: Single-chain antigen binding proteins. Science (1988) 242:423-426.
16. JOHNSON S, BIRD RE: Construction of single-chain Fv derivatives of monoclonal antibodies and their production in Escherichia coli. Meth. Emymol (1991) 203:88-98.
17. HUSTON JS, LEVINSON D, MUDGETT-HUNTERM et al.: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxir single-chain Fv analogue produced in Escherichia coli. Proc. NatL Acad. Sei USA (1988) 85:5879-5883-
18. CHAUDARYVK, QUEEN C, JUNGHANS RP, WALDMAN TA, FITZGERALD DJ, PASTAN I: A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomoras exotoxin. Nature (1989) 339:394-397.
19. GLOCKSHUBER R, MALIA M, PFITZINGER I, PLOCKTHUN A: A comparison of strategies to stabilise immunoglobulin Fv-fragments. Biochemistry (1990) 29:1362-1367.
20. WEBBER KO, REITER Y, BRINKMANN U, KREITMAN RJ, PASTAN I: Preparation and characterisation of a disulfide-stabilised Fv fragment of the anti-Tac antibody. Comparison with its single-chain analogue. MoL ImmunoL (1995) 32:249-258.
21. BATRAJK, FITZGERALD D.GATELYM CHAUDARYVK, PASTAN I: Anti-Tac(Fv) PE40, a single-chain antibody Pseudonwnas exotoxin fusion protein directed at interleukin-2 receptor bearing cells. J. BioL Chem. (1990) 265:15198-15202.
22. BATRAJK, KASPRZYK PG, BIRD RE, PASTAN I, KING CR: Rccombinant antierbB2 immunotoxins containing Pieudomoras exotoxin. Proc. NatL Acad. Sei. USA (1992) 89:5867-5871.
23. WELS W, HARWERTH I, MUELLER M, GRONERB, HYNES NE: Selective inhibition of tumour cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. (1992) 52:6310-6317-
24. REITER Y, BRINKMANN U, LEE BK, PASTAN I: Engineering antibody fv fragments for cancer detection and therapy: disulfide-stabilised Fv fragments. Nature BiotechnoL (1996) 14:1239-1245.
25. • A thorough review of the design strategy,
26. construction, production and biochemical features of various dsFvs and dsFv-fusion proteins.
27. BERA TK, ONDA M, BRINKMANN U, PASTAN I: A bivalent dtsulfide-stabilised Fv with improved antigen binding to erbB2. ]. Mol BioL (1998) 281:475-483.
28. REITER Y, BRINKMANN U, JUNG SH, LEE B, KASPRZYK PG, KING CR, PASTAN I: Improved binding and and tumour activity of a recombinant anti-erbB2 immunotoxin by disulfide-stabilisation of the Fv fragment.J. BioL Chem. (1994) 269:18327-18331.
29. JUNG SH, PASTAN I, LEE BK: Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins (1994) 19:357.
30. BRINKMANN U, REITER Y, JUNG SH, LEE BK, PASTAN I: A recombinant immunotoxin containing a disulfidestabilised Fv fragment. Proc. NatL AcaJ. Sei. USA (1993) 90:7538-7542.
31. REITER Y, PAILH, BRINKMANN U, WANG QC, PASTAN I: antitumour activity in mice of a recombinant immunotoxin containing a disulfide-stabilised Fv fragment. Cancer Res. (1994) 54:2714-2718.
32. BENHARI, REITER Y, PAI LH, PASTAN I: Administration of disulfide-stabilised immunotoxins Bl (dsFv)-PE38 and B3 (dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumour xenografts in nude mice. Int.]. Gz7Kw(1995) 62:351-355.
33. REITER Y, BRINKMANN U.KREITMAN RJ, JUNG SH, LEE BK, PASTAN I: Stabilisation of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry (1994) 33:5451-5459.
34. REITER Y, PASTAN I: Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends BiotechnoL (1998) 12:513-520.
35. REITER Y, PAI LH, BRINKMANN U, WANG QC, PASTAN I: Antitumour activity in mice of a recombinant immunotoxin containing a disulfidestabilised Fv fragment. Cancer Res. (1994) 54:2714-2718.
36. RAJGOPALV, PASTAN I, KREiTMANRJ: A form of anti-Tac (Fv) which is both singlechain and disulfide-stabilised: comparison with its single-chain and disulfide-stabilised homologues. Protein Eng. (1997) 10:14531459.
37. KOBAYASHI H, HAN ES, KIM IS: Similarities in thé biodistribution of iodenelabelled anti-Tac single-chain disulfïdestabilised Fv fragment and anti-Tac disulfîde-stabilised Fv fragment. Nut. Med. BioL (1998) 25:387-393.
38. BRINKMANN U: Recombinant toxins: protein engineering for cancer therapy. Moi Med. Today (1996) 2:439-446.
39. McCAFFERTY J, GRIFFITHS AD, WINTER G, CHISWELL DJ: Phage antibodies: filamentous phage displaying antibody variable domains. Nature (1990) 348:552-554.
40. VITETTA ES:From the basic science of B cells to biological missiles at the bedside. Immunology (1994) 153:1407-1420.
41. KREITMANRJ.PASTAN I: Recombinant single-chain immunotoxins against T and B cell leukaemias. Leuk. Lymfhoma (1994) 13:1-10.
42. ALLURED VS, COLLIER RJ.CARROLL SF, McKAY DB: Structure of exotoxin A of Pseudômonas aeruginosd at 3.0-Angstrom resolution. Prof. NatL Acad. Sei. USA (1986)83:1320-1324.
43. HWANG J, FITZGERALD DJ, ADHYA S, PASTAN I: Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E colt. Cell (1987)48:129-136.
44. KOUNNAS MZ, MORRIS RE, THOMPSON MR, FITZGERALD DJ, STRICKLAND DK, SAELINGER CB: The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalises Pseudomonas exotoxin A.J. BioL Chem. (1992) 267:12420-12423.
45. BATRAJK,JINNOY,CHAUDARYVKrt a!.: Antirumour activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc. NatL Acad. Sei. USA (1989) 86:8545-8549.
46. STUDIER FW, ROSENBERG AH, DUNN JJ, DUBENDORFF JW: Use of T7 polymerase to direct expression of cloned genes. Meth. EnzymoL (1990) 185:60-89.
47. RUDOLPH R, LILIE H: In vitro folding of inclusion body proteins. FASEBJ. (1996) 10:49-56.
48. RUDOLPH R and LILIE H: In vitro folding of inclusion body proteins. FASEB J. (1996) 10:49-56.
49. LILIE H, SCHWARZ E, RUDOLPH R: Advances in refolding of proteins produced
50. in £coll. Curr. Of in. BiotechnoL (1998) 9:497-501.
51. BUCHNERJ, PASTAN I, BRINKMANN U: A method to increase the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem. (1992) 205:263-270.
52. BRINKMANN U, PAILH, FITZGERALD DJ, WILLINGHAM M, PASTAN I: B3(Fv)-PE38, a single chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. NatL Acad. Sei. USA (1991) 88:86168620.
53. ENGERT A, MARTIN G, AMLOT P, WIJDENES J, DIEHL V, THORPE P: Immunotoxins construaed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int. J. Cancer (1991) 49:450-456.
54. GHETIE M-A, RICHARDSON J, TUCKER T, JONES D, UHR JW, VITETTA ES: Ami tumour activity of Fab and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumour cells in extranodal sites. Cancer Res. (1991) 51:5876-5880.
55. SKREPNIK N, ZIESKE AW. ROBERT E, BRAVO JC, MERA R, HUNT JD: Aggressive administration of recombinant oncotoxin AR209 (anti-ErbB2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours. Bur. J. Cancer (1998) 34:1628-1633.
56. PAI LH, PASTAN I: Clinical trials with Pseudomonas exotoxin immunotoxins. Curr. Topics MicrobioL ImmunoL (1998) 234:8396.
57. PURIRK,HOONDS,LELANDP: Preclinical develop ment of a recombinant toxin containing circularly permutated interleukin 4 and truncated Pseudomonas exotoxin for therapy in malignant astrocytoma. Cancer Res. (1996) 56:56315637.
58. AMLOT P, STONE MJ, CUNNINGHAM D étal: A Phase I study of an anti-CD22-dcglycosyIated ricin A chain immunotoxin in the treatment of Bcell lymphomas resistant to conventional therapy. AW(1993) 82:2624-2633.
59. SAUSVILLEEA,HEADLEED, STETLER-STEVENSON M ttal.:
60. Continuous infusion of the anti-CD22immunotoxin IgG-RFB4-SMPT-dgA in patients \vith B-cell lymphoma: a Phase I study. Blood (1995) 85:3457-3465.
61. CONRZ RM, KHAZAELI MB, SALEH MN et al.: Phase I trial of an Anti-CD19deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.J. Immunothir. (1995) 18:231-241.
62. MULTANI PS, O'DAY S, NADLER LM, GROSSBARD ML- Phase II clinical trial of bolus infusion ami-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. (1998) 4:2599-2604.
63. KREITMAN RJ, PASTAN I: Targeting PseuJomonas exotoxin to haematological malignancies. Sem. Cancer BioL (1996) 6:297-306.
64. KREITMAN RJ, WILSON WH, STETLER-STEVENSON M et al.: High complete remission rate in chemotherapyrefractory classic or variant hairy cell leukaemia induced by the anti-CD22 recombinant immunotoxin RFB4 (dsFv)PE38 (BL22). AW (2000) 96:577a Abstract 2477.
65. •• A detailed abstract of the fascinating clinical results of a phase I trial with the anti-CD22 immunotoxin BL22.
66. KREITMAN RJ, WILSON WH, ROBBINS D et al.: Responses in refractory hairy cell leukaemia to a recombinant immunotoxin. £AW(1999) 94:3340-3348.
67. KREITMAN RJ, WILSON WH, WHITE JD et al.: Phase 1 trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB2) in patients with haematological malignancies.J. Clin. OncoL (2000) 18:1622-1636.
68. Report on the first recombinant immunotoxin to induce major responses in cancer (LMB-2).
69. MONTAGNA D, WON E, CALCATERRA V et al.: Depletion of alloreactive T cells by a specific antiinterleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukaemia and antiviral activity. Blood (1999) 93:3550-3557-
70. LEMAISTRECF, SALEH MN.KUZEL TM et al.: Phase I trial of a ligand fusionprotein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. AW(1998) 91:399-405.
71. JAIN RK: Delivery of molecular medicine to solid tumours. Science (1996) 271:1079-
72. PAI LH, WITTES R, SETSERA, WILLINGHAM MC, PASTANI: Treatment of advanced solid tumours with immunotoxin LMB-1: an antibody linked to Pseudomonas Exotoxin. Nature Med. (1996) 3:350-353.
73. First report on antitumour activity of an immunotoxin (LMB-1) in epithelial tumours.
74. CHOWDHURY PS, VINER JL, BEERS R, PASTAN I: Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunised mice by phage display and construction of a recombinant immunotoxin with antitumour activity. Proc. Natl Acad. Sei. USA (1998) 95:669-674.
75. • Report on the isolation of a scFv against mesothelin.
76. GOLDBERG MR, HEIMBROOK DC, RUSSO P et al.: Phase I clinical Study of recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Rts. (1995) 1:57-61.
77. FOSSFM.SALEHMN.KRUEGERJG, NICHOLS JC, MURPHY JR: Diphteria toxin fusion proteins. In Clinical Apflicatioru oflmmunotaxim. Frankel AE (Ed.), Berlin: Springer-Verlag (1998): 6381.
78. PAI-SCHERFLH,VILLAJ,PEARSOND et al.: Hepatotoxicitiy in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2
79. receptor. Clin. Cancer Res. (1999) 9:23112315-
80. LORIMERIAJ, KEPPLER-HAFKEMEYERA, BEERS RA, PEGRAM CN, BIGNER DD, PASTAN I: Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc. NatLAcaJ. Sei. USA (1996) 93:14815-14820.
81. KUANCT.WIKSTRANDCJ, ARCHER G et al.: Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specificscFv./nf.J. Cancer (2000) 88:962-969.
82. RANDRW.KREITMANRJ.PATRONAS N, VARRICHIO F, PASTAN I, PURI RK: Intratumoural administration of recombinant circularly permuted interIeukin-4-/i
83. LASKEDW.YOULERJ.OLDFIELDEH: Tumour regression with regional distribution of the targeted toxin TFCRM107 in patients with malignant brain tumours. Nature Med. (1997) 12:13621368.
84. KREITMAN RJ: Immunotoxins in cancer therapy. Curr. Of in. ImmunoL (1999) 11:570-578.
85. SIEGALL CB, HAGGERTY HG, WARNER G L et al.: Prevention of
86. immunotoxin-induced immunogenicity by co-administration with CTLA4lg enhances antitumour effects.J. ItnmunoL (1997) 159:5168-5173.
87. TSUTSUMIY, ONDA M, NAGATA S, LEE BK, KREITMAN, RJ, PASTAN I: Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) improves antitumour activity and reduces animal toxiciry and immunogenicity. Proc. NatlAcad. Sei. USA (2000) 97:8548-8553.